Company Performance Analyst Ratings Market Trends Valuation Metrics Earnings Reports Company Valuation Price Targets Market Volatility Price Target Price-to-Earnings Ratio Market Performance Performance Metrics Target Price Portfolio Management Volatility Market Capitalization Investor Sentiment Technical Indicators Dividend Yield Support and Resistance Levels Valuation Brokerage Reports Growth Stocks Market Reactions Gainers and Losers Hedge Funds Technical Analysis Equity Valuation Firm Valuation Investment Tips Earnings Investment Ratings Target Price Predictions Value Stocks Coca-Cola Growth Rates Value Investing Company Guidance Revenue Growth Downgrades Semiconductors Nvidia Qualcomm Earnings Multiples Stock Price Performance Earnings Estimates Quarterly Results Public Companies Market Positioning Jim Cramer Momentum Indicators Comparative Valuation Share Price Movement Market Forecasts Market Sentiment Dividend Stocks P/E Ratio Company Reports Market Ratings Investment Recommendations Wall Street Bank of America Market Corrections S&P 500 Comparison Investor Strategies Growth Investing Technology Stocks Market Predictions Share Buybacks Investment Strategies Investment Opportunities Sector Performance Long-term Investments Company Evaluation Oversold Stocks Top Companies Quantum Computing Analyst Recommendations Investment Philosophy Price Movement DAX Index Share Price Target Company Fundamentals AI Stocks Company Comparisons
Sales were led by injectable GLP-1 treatments that now face pressure from cheaper pills.
